ClearPoint Neuro, Inc. cash flow to debt ratio of -41.09% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ClearPoint Neuro, Inc.'s free cash flow has decreased 165.01% from $-9.22M last year to $-24.45M, signaling decreasing performance

ClearPoint Neuro, Inc.'s debt to equity ratio is 3.38, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

ClearPoint Neuro, Inc.'s debt has increased relative to shareholder equity from 0.14 last year to 3.38 today, signaling weakened financials

ClearPoint Neuro, Inc. has negative EBITDA, making leverage ratio unreliable

ClearPoint Neuro, Inc.'s interest coverage ratio is -9.78, which means that the company struggles to meet interest obligations, signaling financial risk.

ClearPoint Neuro, Inc.'s profit margin has decreased (18.77%) in the last year from -60.25% to -71.57%, signaling decreasing performance

ClearPoint Neuro, Inc.'s short-term assets of $63.60M exceed its short-term liabilities of $10.77M

ClearPoint Neuro, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ClearPoint Neuro, Inc.'s return on equity of -140.96%, is lower than 15.00%, indicating bad performance

ClearPoint Neuro, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ClearPoint Neuro, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

ClearPoint Neuro, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

ClearPoint Neuro, Inc. has negative free cash flow, indicating cash burn

ClearPoint Neuro, Inc.'s yearly earnings has decreased 35.03% since last year from $-18.91M to $-25.54M, signaling decreasing performance

ClearPoint Neuro, Inc.'s yearly revenue has increased 17.78% since last year from $31.39M to $36.97M, signaling increasing performance

ROIC -31.46% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ClearPoint Neuro, Inc.'s 3-year revenue CAGR of 21.62% is positive, indicating growing revenue over the past 3 years

ClearPoint Neuro, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

ClearPoint Neuro, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

ClearPoint Neuro, Inc. has insufficient data to evaluate this check.

ClearPoint Neuro, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ClearPoint Neuro, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ClearPoint Neuro, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ClearPoint Neuro, Inc. is overvalued relative to its fair value price of -20.08 based on Earnings Fair Value model

ClearPoint Neuro, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ClearPoint Neuro, Inc. has a price-to-book ratio of 25.03x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

ClearPoint Neuro, Inc. has a price-to-sales ratio of 11.61x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue